VALNEVA (VLA FP / VALN) — FY2025 Results & 2026 Guidance: Below Consensus, But the Story is Binary
Numbers vs. Expectations
The top-line scorecard is a modest disappointment on guidance, but clean at the actuals level:
| Metric | FY2025 Actual | FY2026 Guidance | Consensus |
| Total Revenues | €174.7m ✅ | €155–170m | €175.6m ❌ |
| Product Sales | €157.9m | €145–160m | — |
| Adj. EBITDA | –€59.4m | — | — |
| Net Loss | –€115.2m | — | — |
| Cash | €109.7m | — | — |
FY2025 revenues of €174.7m came in exactly in line with the company's own guidance and slightly above FY2024's €169.6m, including a variable consideration recognition from the Lyme disease collaboration with Pfizer.
The miss is entirely in the forward look: 2026 total revenue guidance of €155–170m falls short of FactSet consensus of €175.6m — a midpoint shortfall of roughly €13m or ~7.5%. This is not a collapse; it is a deliberate mix shift management has signalled for several quarters.
The Third-Party Sales Wind-Down — Known, Not New
The single biggest driver of the guidance gap is the accelerating exit from low-margin third-party distribution. Third-party product sales fell to €19.2m in 2025 from €33.2m in 2024, a 42% decline — a planned reduction — while proprietary product sales grew 9% at constant exchange rates excluding third-party items.
This is the correct read: the underlying commercial engine (IXIARO, DUKORAL, IXCHIQ) is actually accelerating. The revenue haircut in 2026 guidance is a quality-of-earnings improvement, not demand deterioration. Consensus had arguably not fully adjusted for the pace of third-party wind-down.
IXCHIQ — The Overhang That Lingers
IXCHIQ sales in 9M 2025 were €7.6m vs. €1.8m in 9M 2024, boosted by supply to La Réunion during a chikungunya outbreak, but a U.S. license suspension significantly constrained the travelers' segment. The FDA situation remains an open item — no resolution has been announced as of today's results. This is the key near-term commercial risk that the market will interrogate on the webcast.
The Only Thing That Matters: VALOR Phase 3 Data
Everything else is noise. Management is flagging 2026 as potentially transformational, with Phase 3 VALOR data for VLA15 expected in H1 2026, followed by Pfizer targeting BLA submission to the FDA and MAA to the EMA in 2026 subject to positive results.
Context on VALOR:
- The VALOR trial enrolled 9,437 participants aged 5 and older across the US, Europe, and Canada in Lyme-endemic areas.
- Phase 2 data has been consistently clean: seroconversion rates above 90% for all six OspA serotypes across pediatric, adolescent, and adult groups.
- The one historical red flag: in February 2023, Pfizer discontinued approximately half of US participants due to GCP violations at third-party clinical trial sites — unrelated to safety. This forced re-enrollment and delayed timelines but did not impair the scientific thesis.
Lyme disease vaccine market potential is substantial: ~476,000 annual US diagnoses and ~130,000 in Europe, with zero approved human vaccines globally. First-mover advantage with Pfizer's commercial infrastructure behind it is a genuinely differentiated asset.
Cash & Balance Sheet
Year-end cash of €109.7m following successful debt refinancing provides enhanced financial flexibility. With adj. EBITDA losses of €59.4m and management guiding for further reduction in operating cash burn in 2026, the company has runway through the VALOR readout without obvious dilution risk — a key concern that has historically weighed on the stock.
Read-Across for Your Fiche Biotech Universe
A few relevant signals for your broader coverage:
- VALOR success scenario is a positive read-across for any infectious disease/vaccine name with binary Phase 3 catalysts — sets a constructive tone for biotech event risk appetite into H1 2026.
- Pfizer BLA/MAA filing in 2026 (if data positive) would be one of the most significant vaccine regulatory events of the year — watch for co-commercialisation milestone payments flowing to Valneva (material to its P&L).
- Negative VALOR scenario would likely be severe for VLA — the stock would re-rate entirely on the commercial franchise alone, which at guidance midpoint (~€162.5m revenues, still loss-making) is worth considerably less than current market cap.
Bottom Line
The guidance miss is real but largely mechanical (third-party wind-down, FX, IXCHIQ US headwind). The commercial franchise ex-third-party is growing. The binary is VALOR: positive data in H1 2026 is transformative; negative is devastating. The stock is a levered option on VLA15, dressed in a travel vaccine wrapper. The CFO's comment about "resilience" and "disciplined execution" is the right tone — management is not over-promising. Watch the webcast closely for any colour on VALOR data timing within H1 and any FDA IXCHIQ update.